VEGFA and neoplasm: Additionally, accumulated evidence has indicated that a substantial proportion of neoplasms had either inherent or acquired resistance to bevacizumab during VEGF blockade targeted therapy, which has significantly undermined the clinical application of anti‐angiogenic regimens [3].